RGS 0.00% 12.0¢ regeneus ltd

novel canine cancer vaccine gets green light, page-12

  1. 3,752 Posts.
    lightbulb Created with Sketch. 77
    CRITERION
    From: The Australian
    November 15, 2013 12:00AM

    Regeneus (RGS) 37c

    STILL on our furry friends, shares in the stem-cell play enjoyed a 9c, 32 per cent rocket yesterday after the recently listed entity won consent from US
    veterinary gatekeepers to commercialise its novel canine cancer vaccine.

    The remedy is derived from material from the ailing hound's own tumour or biopsy. The treatment has been tested on 40 dogs with life-threatening cancers.

    Of these, 80 per cent survived for longer than they might have.

    Regeneus' main game is treatments for human inflammatory ailments such as osteoarthritis. But is this one a case of the tail wagging the dog? Hold.

    - See more at: http://www.theaustralian.com.au/business/opinion/greencross-a-
    long-term-vet-as-it-dogs-big-guys/story-e6frg9lo-
    1226760181440#sthash.VJVt8REy.dpuf
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.